Title : The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

Pub. Date : 2020 Feb 19

PMID : 32075643






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Somatic mutations of KIT determine the constitutive activation of the tyrosine kinase receptor leading to a worse prognosis and a shorter survival time than MCTs harbouring wild-type KIT. Tyrosine KIT proto-oncogene, receptor tyrosine kinase Canis lupus familiaris
2 However, canine MCTs carrying KIT somatic mutations generally respond well to tyrosine kinase inhibitors; hence their presence represents a predictor of treatment effectiveness, and its detection allows implementing a stratified medical approach. Tyrosine KIT proto-oncogene, receptor tyrosine kinase Canis lupus familiaris
3 Molecular profiling of the tumoural masses revealed two different mutations; other than the already known activating mutation p.Asn508Ile in KIT exon 9, which is tyrosine kinase inhibitor-sensitive, a nearly adjacent secondary missense mutation, p.Ala510Val, which had never before been described, was detected. Tyrosine KIT proto-oncogene, receptor tyrosine kinase Canis lupus familiaris